These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 25377640)

  • 21. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
    Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
    Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
    Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
    J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
    Teo MC; Tan GH; Tham CK; Lim C; Soo KC
    Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases.
    Kyang LS; Alzahrani NA; Valle SJ; Rahman MK; Arrowaili A; Liauw W; Morris DL
    J Surg Oncol; 2019 Sep; 120(4):794-802. PubMed ID: 31309588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Doud AN; Randle RW; Clark CJ; Levine EA; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2015 May; 22(5):1645-50. PubMed ID: 25120249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures.
    Passot G; Vaudoyer D; Villeneuve L; Kepenekian V; Beaujard AC; Bakrin N; Cotte E; Gilly FN; Glehen O
    J Surg Oncol; 2016 Jun; 113(7):796-803. PubMed ID: 27110915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement.
    Franssen B; Tabrizian P; Weinberg A; Romanoff A; Tuvin D; Labow D; Sarpel U
    Ann Surg Oncol; 2015 May; 22(5):1639-44. PubMed ID: 25216604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis from rare etiologies.
    Mah M; Mack LA; Hurton S; Bouchard-Fortier A
    Am J Surg; 2019 May; 217(5):923-927. PubMed ID: 30760409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Munoz-Zuluaga C; Sardi A; King MC; Nieroda C; Sittig M; MacDonald R; Gushchin V
    Ann Surg Oncol; 2019 Feb; 26(2):473-481. PubMed ID: 30523470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival.
    Wagner PL; Austin F; Maduekwe U; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2013 Apr; 20(4):1056-62. PubMed ID: 23456385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
    Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
    Canbay E; Mizumoto A; Ichinose M; Ishibashi H; Sako S; Hirano M; Takao N; Yonemura Y
    Ann Surg Oncol; 2014 Apr; 21(4):1147-52. PubMed ID: 24356799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
    Hotopp T
    Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.